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BACKGROUND: Human papillomavirus (HPV) vaccination has been approved in more than 90 countries and is being implemented in
many of these. In the UK, vaccination for girls aged 12–13 with catch-up for girls up to age 18 was introduced in 2008, using the
bivalent GSK vaccine (Cervarix).
METHODS: We modelled the proportion of abnormal smears, cervical intraepithelial neoplasia grade 3 (CIN3) and invasive cancer,
which will be prevented in women aged 20–29 in the UK as a result of HPV vaccination.
RESULTS: It will take many years for the full benefit of vaccination to be achieved. The earliest effects will be seen in women aged
20–29. With 80% coverage in women aged 12–13, we project an eventual 63% reduction in invasive cancer, a 51% reduction in
CIN3 and a 27% reduction in cytological abnormalities before age 30. The full effect in this age group will not be seen until 2025,
although half of the benefit will be seen by 2019 in England, where screening starts at age 25. However in Scotland and Wales, where
screening starts at age 20, 50% of the benefit for CIN3 and abnormal smears (but not cancer) will be seen earlier.
CONCLUSION: Substantial reductions in disease can be anticipated by vaccination, but most of the benefit will not be apparent for at
least another decade. High vaccine coverage is the key factor for achieving these benefits.
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High-risk human papillomavirus (HPV) types have been found in
more than 95% of women with invasive cervical cancer
(Walboomers et al, 1999). The greatest proportion is caused by
HPV 16, found in about 55% of these cancers worldwide, but
higher in the UK and Western Europe (WHO/ICO Information
Centre on HPV and Cervical Cancer, 2007) followed by HPV 18
(found in about 16%) (Smith et al, 2007).
To date two vaccines that protect against HPVs 16 and 18 are
commercially available, Gardasil (Merck, West Point, PA, USA) and
Cervarix (GSK, Brentford, London, UK), for intramuscular use in
three doses over 6 months; Gardasil also protects against HPVs
6 and 11, which cause genital warts. The vaccines also differ by the
type of adjuvant used. Vaccination after infection appears to have
no therapeutic value for either vaccine. Several randomised trials
have been reported for each vaccine. The phase III trials focused on
persistent infection and cervical intraepithelial neoplasia (CIN)
associated with the relevant HPV types (Harper et al, 2004, 2006;
FUTURE II Study Group, 2007; Garland et al, 2007; Paavonen et al,
2009). Additional smaller phase II trials were primarily to evaluate
immune response (Mao et al, 2006; Villa et al,2 0 0 6 ) .
Human papillomavirus vaccination, approved in more than 90
countries, is being implemented in many. In the UK, vaccination for
girls aged 12–13 with catch-up for girls up to age 18 was introduced
in September 2008 using Cervarix (Table 1). The programmes in the
4 nations (England, Scotland, Wales, N Ireland) are very similar, but
there are slight differences in the catch up provision. As the impact
of vaccination will first become apparent in younger women, we
have estimated the number of abnormal smears, CIN grade 3 lesions
(CIN3) and invasive cancers, which will be prevented by HPV
vaccination at ages 20–29 in the UK. Because CIN3 and abnormal
smears are only relevant in screened population that in England
does not include ages 20–24 (but does in Scotland, Wales and
Northern Ireland), we estimate these end points, both in the
presence and absence of screening in this age group.
MATERIALS AND METHODS
Because vaccination is only effective in uninfected women, the
impact of the catch-up programme presents difficulties in
modelling, due to the higher pre-exposure to HPV at the time of
vaccination. We modelled the proportion of each of the three end
points that will be prevented by the UK vaccination programmes at
different calendar time points. This was done separately for HPV
16 and HPV 18 for each end point.
In our model, the relative protection afforded by vaccination
depends on the product of four factors:
(1) The proportion of the disease end point caused by HPV types
16, 18, 31, 33 and 45.
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afforded by vaccination before infection (this is assumed to be
100% for types 16 and 18, but lower for types 31, 33 and 45
when cross-protection is included and 0 when no cross-
protection is included).
(3) The relative protection in older girls compared with a girl
vaccinated at age 13 (Table 2). For vaccination at age 16 (for
example), this is based on the proportion of disease occurring
before age 30 that is caused by infection before age 16. This is
assumed to be independent of the type of HPV.
(4) The likelihood of being vaccinated. This is expressed relative
to the coverage in girls aged 12–13 who would be offered
vaccination as part of a school-based programme (Table 2).
Factors 1 and 2 are taken to be independent of age (under 30)
and calendar year. Factors 3 and 4 are determined at the time of
vaccination and carried forward as the woman ages. We calculate
the number of events expected in single year age groups and then
present the (average) rate in combined age groups (20–24, 25–29
and 20–29).
Assumptions
The HPV vaccine programme in the UK is primarily school based.
Provisional data submitted by Primary Care Trusts in England by the
30 April 2009 report that 86.2% of girls aged 12–13 have had their
first HPV jab and 82.6% have received their second jab (NHS
Immunisation Information, 2009). Coverage in the catch-up cohort
(much of which is not in full-time education) is much lower with
52.5% of 17- to 18-year olds receiving the first dose and 40.8%
receiving the second (NHS Immunisation Information, 2009).
The vaccine uptake figures (which include vaccinations from
September 2008 to mid-February 2009) for Scottish girls in the
second, fifth and sixth year of secondary school are 92.2% for the
first dose and 87.8% for the second dose (Information Services
Division NHS National Services Scotland, 2009). Uptake figures for
girls that are no longer at school have not been published, but they
will be substantially lower. Furthermore Australia’s latest coverage
report (published December 2008), including data from all three
vaccine doses, suggests a 70% coverage for school-based
programmes across all cohorts vaccinated (school years 7–12)
(Brotherton et al, 2008).
On the basis of these experiences, our base case assumption is
that coverage will be 80% at age 12–13 and somewhat lower at
older ages (Table 2), but we also present estimates based on 70 and
100% coverage at age 12–13. The relative protection afforded by
100% coverage corresponds to the protection in vaccinated
women.
HPV exposure before vaccination Data from the vaccine trials
indicate that vaccination does not convey protection once the
subject has been exposed to the virus (Schiller et al, 2008).
However women infected by one type are still protected against the
other type. Thus, for example, women infected with HPV type 18
only before vaccination will still benefit from vaccination, but
the benefit will be less than in women naive to both types at
vaccination. The relative protection of vaccinating a group of
women some of whom have been infected compared to a group
who are still naive depends not only on the proportion infected
before vaccination but also the proportion who will eventually
become infected in the absence of vaccination. Thus, for instance,
if 50% would be infected with HPV 16 by age 30, and 10% are
already infected before vaccination, then the effect of the vaccine,
against HPV 16-induced disease, is only 80% of that achieved in a
naive population.
Statistics from the United States estimate that approximately
13% of women aged 15 have ever had sex (Guttmacher Institute,
2006) and a survey in the UK estimated that 26% of women had
had sex by age 16 (Wellings et al, 2001). Based on this evidence, it
is very likely that most girls aged 12–13 will be HPV naive at the
time of vaccination, but that the benefit of vaccination will be
attenuated in the catch-up group. We anticipate 30–40% of
women to be sexually active by age 17 and around 70% by age 19
(Wellings et al, 2001; Guttmacher Institute, 2006). Evidence
suggests that women become HPV positive shortly after they
become sexually active. In a cohort of HPV-negative young women
in the USA, 17% were found to be HPV positive within 12 months
and 55% within 3 years of entry into the study; 59% of HPV-
positive women were infected with a high-risk HPV type (Moscicki
et al, 2001). Approximately half of those testing high-risk HPV
positive (for a pool of high-risk types) will have an infection
with type 16 or 18 (Hibbitts et al, 2008; Sargent et al, 2008).
Furthermore a recent study found that the mean time between
Table 2 Estimated relative protection and coverage for vaccination at
different ages relative to girls vaccinated at age 12–13
Year of
birth
a
Age at
vaccination
(third dose)
Relative protection
compared to those
vaccinated aged
12–13
b (%)
Relative coverage
compared to
those aged
13
c (%)
1996 or after 13 100 100
1995 15 97 95
1994 16 92 75
1993 17 77 50
1992 18 70 50
1991 18 70 50
1990 or before Not vaccinated 0 0
No protection against invasive cervical cancer from catch-up within 8 years of
vaccination.
aFor example, a year of birth of 1994 means September 93 to August 94
and assumes that the majority would have a birthday by the third dose.
bLower
protection comes primarily from some teenagers being infected with either type 16
or 18 HPV before vaccination.
cLower coverage (particularly for those born in 1991–
1993) is due to the non-school-based vaccine programmes.
Table 1 Birth cohorts for English HPV vaccination schedule
Academic year
HPV vaccine
given
School
year 7
School year 8
Age 12–13
School
year 9
School
year 10
School year 11
Age 15–16
School year 12
Age 16–17
School year 13
Age 17–18
2008/09 1 Sep 1995 to
31 Aug 1996
1 Sep 1990 to
31 Aug 1991
2009/10 1 Sep 1996 to
31 Aug 1997
1 Sep 1994 to
31 Aug 1995
1 Sep 1993 to
31 Aug 1994
1 Sep 1992 to
31 Aug 1993
1 Sep 1991 to
31 Aug 1992
2010/11 1 Sep 1997 to
31 Aug 1998
2011/12 1 Sep 1998 to
31 Aug 1999
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intraepithelial lesions related to HPV 16 or 18 was 3.6 years
(Trottier et al, 2009). However, the evidence suggests that cervical
cancer only rarely develops within 8 years of HPV infection so that
the catch-up programme in 16- to 18-year olds may have an effect
on abnormal smears and CIN rates before age 30 but is likely to
have only a minimal impact for cancer before this age. We assume
that there will be no effect on cancer incidence within 8 years of
vaccination and that the effect thereafter will depend on the age at
vaccination. Assumptions made about the protection obtained
from catch-up vaccination are detailed in Table 2. We assume the
relative protection given to women vaccinated within the catch-up
programme will be 70% or higher (Table 2). This roughly
corresponds to 15% of 17- to 18-year olds already being infected
with HPV 16 or 18 and 50% becoming infected by age 30 in the
absence of vaccination. The results presented are robust to even
substantial changes to the assumptions in Table 2. For instance we
considered the relative protection at age 17–18 to be as high as
90% or as low as 50%.
We also assume that vaccine coverage in the population as a
whole (sexually active men and women of any age) will be
insufficient over the next 20 years to provide any material herd
immunity.
Cross-protection Both vaccines have reported information re-
garding cross-protection (Brown et al, 2009; Paavonen et al, 2009;
Wheeler et al, 2009). Here we model the effect of cross-protection
using recent results from the PATRICIA trial, as this trial used the
vaccine being offered in the UK (Paavonen et al, 2009). Data on
6-month persistent infection by HPV type indicate that the vaccine
is 75.7% (96.1% CI 60.4–85.7) effective against type 45, 78.7%
(96.1% CI 70.2–85.2) effective against type 31 and 45.7% (96.1% CI
25.1–60.9) effective for type 33. The combined effect against types
31 and 45 was 78% and this is the figure we use in our models.
Although these results are encouraging, the duration of cross-
protection is unknown and may be less than for the types in the
vaccine. Thus we have modelled the effect of vaccination in two
ways, once assuming no cross-protection, and again taking into
account the available evidence on cross-protection from PATRI-
CIA (and assuming no waning of protection by age 30).
However it is still premature to estimate the magnitude of the
effect of cross-protection on cancer incidence precisely.
Lesions attributable to HPV 16/18
Invasive cancer The percentage of all cervical cancers attributable
to HPV 16/18 in Europe has been estimated at 73% (Clifford et al,
2006). However the recent evidence suggests that the proportion of
cancer attributable to HPV types 16 and 18 is higher in younger
women than overall (Bruni et al, 2009).
To estimate the proportion of cancers in women aged 20–29
attributable to HPV 16/18, we have used data on HPV 16
prevalence in 5-year age groups from a WHO/ICO pooled
international study (de Sanjose ´ et al, 2007; Bruni and Ferrer
et al, 2009) to adjust this proportion specifically to women aged
20–29. This study found HPV 16 prevalence in cancers among the
20–29 year olds to be 59.1% (146 out of 247) compared to 50.8%
(4333 out of 8530) for the study population as a whole. For the
estimates in the model we have applied the odds ratio (OR)
between the proportion of 20- to 29-year-old cases with HPV 16
and the proportion of cases at all other ages with HPV 16 (OR 1.40)
to the 73% of all cases with 16 and 18. This yields an estimate of
79.1% for the proportion of cervical cancers in 20- to 29-year-old
women attributable to HPV 16 or 18.
To reflect a degree of cross–protection, we assume the
following: 100% protection against HPV 16/18 (which accounts
for 73% of cancer according to Clifford et al, 2006), 78% protection
against HPV 31 and 45 (which together account for 6.9% (Smith
et al, 2007) of the cancer burden in Europe) and 46% protection
against HPV 33 (which account for 4.4% (Smith et al, 2007) of the
cancer burden in Europe). We can then estimate that by taking
cross-protection into account 80.4% of cervical cancers can be
prevented by vaccination.
Thus, whether we adjust for the greater prevalence of HPV 16
in cancers in young women or the potential additional benefit of
cross-protection we arrive at very similar figures (79.1 vs 80.4%)
of cervical cancer in women aged 20–29 being preventable by
vaccination (Table 3). If we took both effects into account,
a potential reduction of 84.3% is possible, but this is speculative
at this stage.
Cervical intraepithelial neoplasia grade 3 The proportion of
CIN3 attributable to HPV 16/18 in women aged 20–29 who had
CIN3 was obtained from estimates observed in the FUTURE I and
FUTURE II trials using Gardasil. The data suggest that approxi-
mately 63.5% of CIN3 observed in their trials was associated with
HPVs 16 and 18 (Franceschi and Clifford, 2008; Table 3).
If we estimate the degree of cross-protection afforded by the
Cervarix vaccine in the same way as we did for invasive cancer,
we find the following: 100% protection against HPV 16/18 (which
account for 57.5% of CIN3, Smith et al, 2007), 78% protection
against HPVs 31 and 45 (which together account for 9.4% (Smith
et al, 2007) of the CIN3 burden in Europe) and 46% protection
against HPV 33 (which account for 3.96% (Smith et al, 2007) of the
CIN3 burden in Europe). We can then estimate that by taking
cross-protection into account 70.8% of CIN3 can be prevented by
vaccination.
Estimates from the PATRICIA trial from HPV naive women
indicate that the vaccine efficacy against CIN3 or worse lesions
regardless of the HPV type is 87% (96.1% CI 54.9–97.7), however
Table 3 Estimated number and rate of cancers, CIN3 and cytological abnormalities in women under age 30 in and per cent prevented by vaccination
(with and without cross-protection)
Cancer
a
CIN3
a Cytological abnormalities
b
Age group 20–29 20–24 25–29 20–24 25–29
Population at risk 3095000
c 1546000
c 1549000
c 353239
d 414892
d
Annual number of cases 224 4,013 4,996 53 672 47 914
Rate 7.2/10
5 260/10
5 322/10
5 15.2% 11.2%
Per cent prevented in vaccinated women with no cross-protection 79.1% 63.5% 34%
Number prevented with 80% coverage 142 2039 2538 14599 13033
Per cent prevented in women vaccinated with cross-protection 80.4% 70% 26.3%
Number prevented with 80% coverage 144 2247 2798 11164 9966
aCancer Statistics Registrations 2003.
bScreening Programme Statistical Bulletin 2002–2003.
cResident population.
dNumber with an adequate smear test.
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worse. Estimates for CIN2 or worse are based on 143 cases and
indicate a vaccine efficacy of 70.2% (96.1% CI 54.7–80.9). Another
relevant clinical end point is how many women are treated for
cervical disease. The PATRICIA trial observed a 68.8% (96.1% CI
50.0–81.2%) reduction in the number of cervical excision
procedures (Paavonen et al, 2009). Taking into account both the
modelled estimate (70.8%) and these various observed protections,
we use 70% as the protection against CIN3 afforded by vaccination
in HPV naive women (Table 3).
Cytological abnormalities Results for women aged 20–29 from
the ARTISTIC trial report that 28% of borderline or mild and 60%
of moderate or worse cytology outcomes were attributable to HPV
16/18 (Sargent et al, 2008). We have computed estimates of the
total proportion of abnormal smears associated with HPV 16/18 by
weighting these estimates by the proportion of high-grade (20%)
and low-grade (80%) abnormalities observed in women aged
20–29 in the Cervical Screening Programme Statistical Bulletin
2002–2003 (Department of Health, 2003). Thus, we conclude
that 34% of cytological abnormalities (0.28 0.80¼22.4% plus
0.60 0.20¼12%) in women aged 20–29 can be prevented by
vaccination (Table 3).
Direct observation from the PATRICIA trial yielded a more
moderate 26.3% (96.1% CI 14.7–36.4) reduction in referrals to
colposcopy associated with vaccination (Paavonen et al, 2009).
Rates of invasive cancer, CIN3 and cytological abnormalities Rates
of invasive cancer and of CIN3 (carcinoma in situ) were obtained
from the 2003 Cancer Statistics Registrations Bulletin for England
(Office for National Statistics, 2003). This year was chosen because
its figures reflect the screening policy before the change to the age
at which women were invited for screening was raised from 20 to
25. Because the impact on CIN3 and cytological abnormalities is
strongly influenced by whether screening is offered to 20- to 24-
year olds, we have calculated rates for CIN3 separately for woman
aged 20–24 and for those aged 25–29. For invasive cancer, we
assume that results would not initially change if screening were
provided at ages 20–24.
Rates of CIN3 and cancer were estimated for single year of age
for women aged 20–29 (we do this because the rates of cervical
cancer are much lower at age 20–23 than at 24). For CIN3 we used
single year of age data from South East England for 1990–2005
(Sasieni et al, 2009). For invasive cancer we used the single year of
age distribution from the UK in 1971–1997 (Office for National
Statistics, 1999).
In the absence of vaccination, the rate of invasive cancer for
women aged 20–29 is taken to be 7.2 per 100000 per year, the rate
for CIN3 in women aged 20–24 is taken to be 260 per 100000 per
year and 322 per 100000 per year in women aged 25–29 (Table 3).
Using the Cervical Screening Programme Statistical Bulletin
2002–2003 (Department of Health, 2003), we found the rates of
cytological abnormalities per 100 women screened to be 15.2 in
women aged 20–24 and 11.2 in women aged 25–29 (Table 3). No
cases of CIN3 or cytological abnormalities will be detected in
women aged 20–24 in England since screening does not take place
in this age band. Thus, we report separately what might happen in
a population screened from age 20 and in a population screened
from age 25 only. For the latter we assume that starting screening
at age 25 will have only a small effect on the end points detected at
age 25–29 compared to starting screening at age 20. This is
certainly an oversimplification, because one would expect some
carryover of end points that would have been detected before age
25 if screening had taken place. This is likely to lead to increased
disease detection at the first screen past age 25, but there are no
reliable data from which to make an adjustment. Further, the
relative effect of vaccination is not affected by what happens to the
underlying rate of disease detected.
RESULTS
For invasive cancer in women aged 20–29, we project a 63%
reduction in rates by 2025 with 80% vaccine coverage and no
cross-protection, based on an estimated 79% reduction in
vaccinated women. If only 70% coverage is achieved, the reduction
will be more moderate (55%). The reduction in rates taking into
account cross-protection is only slightly higher. These rates are
plotted against calendar year in Figure 1 and suggest that half of
the total benefit on cancer rates achievable by vaccination for this
age group could be achieved by the end of 2019.
We project that the CIN3 rates can be reduced by 51% with
80% coverage and no cross-protection, and by 56% taking into
account the cross-protection observed in the PATRICIA trial.
The reduction in rates of CIN3 due to vaccination is plotted against
calendar year in Figure 2, being much more rapid at ages 20–24
than at 25–29. Assuming women aged 20–24 are screened,
about half of the total benefit in this age group will be achieved
by 2015, while for ages 25–29 this will occur around late 2019/early
2020.
Without cross-protection, and assuming screening begins at age
25, we project that cytological abnormalities can be reduced by
27% with 80% coverage. If screening were to begin at age 20, we
estimate that 34% of these abnormalities would be prevented.
However, using more direct estimates from the PATRICIA trial,
with 80% coverage a more moderate 21% reduction is projected.
Reductions of cytological abnormalities as a function of calendar
time are plotted in Figure 3. Thus, vaccination will reduce the rates
of cytological abnormalities in women under the age of 30 in the
UK, with about half of the total benefit achieved by 2015 at ages
20–24 and by late 2019/early 2020 at ages 25–29.
DISCUSSION
It is clear that vaccination will eventually have a substantial impact
on the rates of invasive cervical cancer and its precursors. However
the relative impact on abnormal cytology is much less than that
observed for cervical cancer and CIN3, due to the larger impact of
other HPV types on this end point. The first effects will be seen in
younger women, but even then it will take 10 or more years to be
appreciable, especially if screening starts at age 25. In England
we will not observe the projected benefit of vaccination on
precursor lesions in women aged 20–24, as the screening
programme only invites women over age 25. In fact (regardless
of vaccination) we are likely to observe an increase in the number
of abnormal smears and CIN3 detected during the first round of
screening (at age 25) compared to historical data, due to prevalent
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Figure 1 Predicted reduction in invasive cancer rates (with 80%
coverage) in women aged 20–29 years.
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started earlier. However the effect should disappear by the second
round of screening.
One of the main uncertainties in modelling the impact of
vaccination is coverage. We have assumed coverage of 80% as this
seems likely for a school-based programme, but estimates based on
70% coverage are also given. We have assumed that vaccination
offers lifetime protection, but the current analysis only requires
protection for the next 18 years (i.e. up to 2025). Data on the
duration of protection offered by HPV vaccines are only available
up to 7.3 years after vaccination (De Carvalh and Roteli-Martin,
2009). These suggest no loss of protection, although the extent of
protection remains unknown for longer periods of time and for
cross-protection from HPV types not included in the vaccine.
Also, it is not clear how much efficacy will be lost if only two
doses of the vaccine are received and also how many women will
fall into this category. Preliminary data on antibody titres suggest
two doses may be as effective as three (Dobson et al, 2009).
However, from experience with similar vaccines, most experts
believe that a single dose is unlikely to be effective; therefore
women who only received one dose are probably best grouped with
unvaccinated women.
Our primary model has assumed no cross-protection, but we
have also evaluated a model reflecting findings on cross-protection
 In populations screened
from age 20
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infection with one HPV type does not weaken the protection
afforded by the vaccine to other types. We used CIN3 as one of our
main end points. Another relevant clinical end point would be the
reduction in women treated for cervical disease, as provided for in
the PATRICIA trial. However the KC65 returns used to produce
screening statistics for colposcopy episodes provide only data on
treatment at first appointment. Because we have been unable to
estimate the baseline number of women who get treated annually
in England by age, it was therefore impossible to make this
calculation.
Another major unknown is whether vaccinated women will
reduce their attendance for screening. This is an important issue as
screening and vaccination have benefits of similar magnitude, so
the benefit of vaccination on cervical cancer incidence could be
fully negated if vaccinated women choose not to be screened.
Furthermore, based on associations with deprivation, it is likely
that girls who are not vaccinated will, as women, be less likely to be
screened. Although it is possible that some cultural or religious
subgroups whose lifestyle puts them at low risk will choose not to
participate in either programme, it seems likely that overall women
who miss out on both programmes will have a greater disease
burden than would be predicted by assuming that non-compliance
to one intervention is independent of non-compliance for the
other. In general non-screened women have a much higher risk
than screened women so reaching this group remains a priority.
Screening by self-sampling based on an HPV test may help to
minimise the disease burden in this group, but developing
methods to achieve a high vaccine coverage in deprived groups
is also important. These issues will also be important for
evaluating the joint cost-effectiveness of screening and vaccination
programmes (Goldhaber-Fiebert et al, 2008).
On a more positive note, it is likely that less frequent screening
using HPV testing will become the norm, and the substantially
greater level and duration of protection for this form of testing may
reduce the disease burden further (Bulkmans et al, 2007; Cuzick
et al, 2008; Dillner et al, 2008). In the long term the combination of
HPV vaccination and screening for HPV DNA promises to make
cervical cancer a very rare disease and eliminate the need for
frequent screening and high rates of colposcopic referral.
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